Table of Contents

2019-2024 Global Human Vaccine Consumption Market Report

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Human Vaccine Consumption 2014-2024
  • 2.1.2 Human Vaccine Consumption CAGR by Region
• 2.2 Human Vaccine Segment by Type
  • 2.2.1 Varicella
  • 2.2.2 Influenza
  • 2.2.3 Polio
  • 2.2.4 Hepatitis A
  • 2.2.5 Rabies
  • 2.2.6 BCG
  • 2.2.7 Hepatitis B
  • 2.2.8 Pertussis, Diphtheria, Tetanus
  • 2.2.9 Pneumococcal
  • 2.2.10 Rota vaccine
• 2.3 Human Vaccine Consumption by Type
  • 2.3.1 Global Human Vaccine Consumption Market Share by Type (2014-2019)
  • 2.3.2 Global Human Vaccine Revenue and Market Share by Type (2014-2019)
  • 2.3.3 Global Human Vaccine Sale Price by Type (2014-2019)
• 2.4 Human Vaccine Segment by Application
  • 2.4.1 Adults
  • 2.4.2 Children
• 2.5 Human Vaccine Consumption by Application
  • 2.5.1 Global Human Vaccine Consumption Market Share by Application (2014-2019)
  • 2.5.2 Global Human Vaccine Value and Market Share by Application (2014-2019)
  • 2.5.3 Global Human Vaccine Sale Price by Application (2014-2019)

3 Global Human Vaccine by Players

• 3.1 Global Human Vaccine Sales Market Share by Players
  • 3.1.1 Global Human Vaccine Sales by Players (2017-2019)
  • 3.1.2 Global Human Vaccine Sales Market Share by Players (2017-2019)
• 3.2 Global Human Vaccine Revenue Market Share by Players
  • 3.2.1 Global Human Vaccine Revenue by Players (2017-2019)
  • 3.2.2 Global Human Vaccine Revenue Market Share by Players (2017-2019)
• 3.3 Global Human Vaccine Sale Price by Players
• 3.4 Global Human Vaccine Manufacturing Base Distribution, Sales Area, Product Types by Players
  • 3.4.1 Global Human Vaccine Manufacturing Base Distribution and Sales Area by Players
  • 3.4.2 Players Human Vaccine Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 Human Vaccine by Regions

• 4.1 Human Vaccine by Regions
  • 4.1.1 Global Human Vaccine Consumption by Regions
  • 4.1.2 Global Human Vaccine Value by Regions
• 4.2 Americas Human Vaccine Consumption Growth
• 4.3 APAC Human Vaccine Consumption Growth
• 4.4 Europe Human Vaccine Consumption Growth
• 4.5 Middle East & Africa Human Vaccine Consumption Growth

5 Americas

• 5.1 Americas Human Vaccine Consumption by Countries
  • 5.1.1 Americas Human Vaccine Consumption by Countries (2014-2019)
  • 5.1.2 Americas Human Vaccine Value by Countries (2014-2019)
• 5.2 Americas Human Vaccine Consumption by Type
• 5.3 Americas Human Vaccine Consumption by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC Human Vaccine Consumption by Countries
  • 6.1.1 APAC Human Vaccine Consumption by Countries (2014-2019)
  • 6.1.2 APAC Human Vaccine Value by Countries (2014-2019)
• 6.2 APAC Human Vaccine Consumption by Type
• 6.3 APAC Human Vaccine Consumption by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe Human Vaccine by Countries
  • 7.1.1 Europe Human Vaccine Consumption by Countries (2014-2019)
  • 7.1.2 Europe Human Vaccine Value by Countries (2014-2019)
• 7.2 Europe Human Vaccine Consumption by Type
• 7.3 Europe Human Vaccine Consumption by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa Human Vaccine by Countries
  • 8.1.1 Middle East & Africa Human Vaccine Consumption by Countries (2014-2019)
  • 8.1.2 Middle East & Africa Human Vaccine Value by Countries (2014-2019)
• 8.2 Middle East & Africa Human Vaccine Consumption by Type
• 8.3 Middle East & Africa Human Vaccine Consumption by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Marketing, Distributors and Customer

• 10.1 Sales Channel
  • 10.1.1 Direct Channels
  • 10.1.2 Indirect Channels
• 10.2 Human Vaccine Distributors
• 10.3 Human Vaccine Customer

11 Global Human Vaccine Market Forecast

• 11.1 Global Human Vaccine Consumption Forecast (2019-2024)
• 11.2 Global Human Vaccine Forecast by Regions
  • 11.2.1 Global Human Vaccine Forecast by Regions (2019-2024)
  • 11.2.2 Global Human Vaccine Value Forecast by Regions (2019-2024)
  • 11.2.3 Americas Consumption Forecast
  • 11.2.4 APAC Consumption Forecast
  • 11.2.5 Europe Consumption Forecast
  • 11.2.6 Middle East & Africa Consumption Forecast
• 11.3 Americas Forecast by Countries
  • 11.3.1 United States Market Forecast
  • 11.3.2 Canada Market Forecast
  • 11.3.3 Mexico Market Forecast
  • 11.3.4 Brazil Market Forecast
• 11.4 APAC Forecast by Countries
  • 11.4.1 China Market Forecast
  • 11.4.2 Japan Market Forecast
  • 11.4.3 Korea Market Forecast
  • 11.4.4 Southeast Asia Market Forecast
  • 11.4.5 India Market Forecast
  • 11.4.6 Australia Market Forecast
• 11.5 Europe Forecast by Countries
  • 11.5.1 Germany Market Forecast
  • 11.5.2 France Market Forecast
  • 11.5.3 UK Market Forecast
  • 11.5.4 Italy Market Forecast
  • 11.5.5 Russia Market Forecast
  • 11.5.6 Spain Market Forecast
• 11.6 Middle East & Africa Forecast by Countries
  • 11.6.1 Egypt Market Forecast
  • 11.6.2 South Africa Market Forecast
  • 11.6.3 Israel Market Forecast
  • 11.6.4 Turkey Market Forecast
  • 11.6.5 GCC Countries Market Forecast
• 11.7 Global Human Vaccine Forecast by Type
• 11.8 Global Human Vaccine Forecast by Application

12 Key Players Analysis

• 12.1 CNBG
  • 12.1.1 Company Details
  • 12.1.2 Human Vaccine Product Offered
  • 12.1.3 CNBG Human Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.1.4 Main Business Overview
  • 12.1.5 CNBG News
• 12.2 Changsheng Life
  • 12.2.1 Company Details
  • 12.2.2 Human Vaccine Product Offered
  • 12.2.3 Changsheng Life Human Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.2.4 Main Business Overview
  • 12.2.5 Changsheng Life News
• 12.3 Zhifei
  • 12.3.1 Company Details
  • 12.3.2 Human Vaccine Product Offered
  • 12.3.3 Zhifei Human Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.3.4 Main Business Overview
  • 12.3.5 Zhifei News
• 12.4 ChengDa Bio
  • 12.4.1 Company Details
  • 12.4.2 Human Vaccine Product Offered
  • 12.4.3 ChengDa Bio Human Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.4.4 Main Business Overview
  • 12.4.5 ChengDa Bio News
• 12.5 Kangtai
  • 12.5.1 Company Details
  • 12.5.2 Human Vaccine Product Offered
  • 12.5.3 Kangtai Human Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.5.4 Main Business Overview
  • 12.5.5 Kangtai News
• 12.6 SINOVAC BIOTECH
  • 12.6.1 Company Details
  • 12.6.2 Human Vaccine Product Offered
  • 12.6.3 SINOVAC BIOTECH Human Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.6.4 Main Business Overview
  • 12.6.5 SINOVAC BIOTECH News
• 12.7 Hissen
  • 12.7.1 Company Details
  • 12.7.2 Human Vaccine Product Offered
  • 12.7.3 Hissen Human Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.7.4 Main Business Overview
  • 12.7.5 Hissen News
• 12.8 Walvax Biotechnology
  • 12.8.1 Company Details
  • 12.8.2 Human Vaccine Product Offered
  • 12.8.3 Walvax Biotechnology Human Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.8.4 Main Business Overview
  • 12.8.5 Walvax Biotechnology News
• 12.9 GSK
  • 12.9.1 Company Details
  • 12.9.2 Human Vaccine Product Offered
  • 12.9.3 GSK Human Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.9.4 Main Business Overview
  • 12.9.5 GSK News
• 12.10 SANOFI
  • 12.10.1 Company Details
  • 12.10.2 Human Vaccine Product Offered
  • 12.10.3 SANOFI Human Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.10.4 Main Business Overview
  • 12.10.5 SANOFI News
• 12.11 Rong An
• 12.12 NuoCheng Bio
• 12.13 Hualan Bio
• 12.14 Tiantan biological
• 12.15 Changchun Baike
• 12.16 Adimmune
• 12.17 Zhongyianke Biotech

13 Research Findings and Conclusion

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins.
China Human Vaccine is widely used for adults and children. The most proportion of China Human Vaccine is children, and the sales market share in 2017 is 64.6%.
The classification of China Human Vaccine includes Varicella, Influenza, Polio, Hepatitis A, Rabies, BCG, Hepatitis B, Pertussis, Diphtheria, Tetanus, Pneumococcal, Rota vaccine and other kinds of vaccines, and the proportion of Rabies in 2017 is about 20.4%.

According to this study, over the next five years the Human Vaccine market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Human Vaccine business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Human Vaccine market by product type, application, key manufacturers and key regions and countries.

This study considers the Human Vaccine value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Varicella
Influenza
Polio
Hepatitis A
Rabies
BCG
Hepatitis B
Pertussis, Diphtheria, Tetanus
Pneumococcal
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Adults
Children

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
CNBG
Changsheng Life
Zhifei
ChengDa Bio
Kangtai
SINOVAC BIOTECH
Hissen
Walvax Biotechnology
GSK
SANOFI
Rong An
NuoCheng Bio
Hualan Bio
Tiantan biological
Changchun Baike
Adimmune
Zhongyianke Biotech

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Human Vaccine consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Human Vaccine market by identifying its various subsegments.
Focuses on the key global Human Vaccine manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Human Vaccine with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Human Vaccine submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.